Glenmark Pharmaceuticals reported a 15.1% increase in consolidated revenue to Rs. 39,006 Mn for Q3 FY26. India business grew by 22.1%. EBITDA was Rs. 8,697 Mn with a margin of 22.3%. The company saw progression in its innovative portfolio, with RYALTRIS® and WINLEVI® scaling across markets and key regulatory approvals achieved. Strategic partnerships in oncology are also set to strengthen Glenmark’s presence in high-need markets.
Financial Performance
Glenmark Pharmaceuticals announced consolidated revenue of Rs. 39,006 Mn for Q3 FY26, representing a year-over-year growth of 15.1%. For the nine months ended December 31, consolidated revenue reached Rs. 132,119 Mn, a 31.3% increase.
Key financial highlights include:
- EBITDA for Q3 FY26: Rs. 8,697 Mn, with a margin of 22.3%
- Net Profit (PAT): Rs. 4,032 Mn with a PAT margin of 10.3%
Regional Performance
The company experienced growth across various key regions:
- India: 22.1% growth
- North America (core business): 4.1% growth
- Europe: 9.1% growth
- Emerging Markets: 8.4% growth
Innovative Portfolio Updates
Glenmark’s innovative portfolio continues to make strides:
- RYALTRIS®: Scaling across markets, with marketing applications submitted in over 90 countries.
- WINLEVI®: Gaining traction in the UK and receiving approval in Europe, with commercial launch in licensed EU territories planned for Q1 FY27.
- Strategic partnerships for oncology assets (including QİNHAYO™™ and Trastuzumab Rezetecan) will strengthen Glenmark’s presence in high-need markets.
India Market Focus
In India, Glenmark outperformed the market with secondary sales growth of 15.8% in Q3 FY26. The company launched the world’s first nebulized fixed-dose triple therapy for COPD.
North America Developments
The company saw core business growth, excluding out-licensing, in North America. They’re awaiting approval for generic nasal sprays and expect additional respiratory products to be filed. The Monroe manufacturing site also received clearance to resume commercial manufacturing.
Source: BSE
